ACQUISITION OFFER - Single Vial System (SVS) technology doubles pharmaceutical supplies at half the cost

BOSTON - Aug. 4, 2016 - PRLog -- Earlier today I notified you of an interview with SVS Medical LLC Founder Prof. Dr. S Tsakas II (Ross). Through this follow-up publication, his new plans for market launch are outlined.

"SVS is exempt from clinical trials and unique registrations with the US FDA, European EMA and UK MHRA as well as exempt from CE certification through both the UK and EU. Moreover, it is merely a storage and reconstitution technology as opposed to a final product that will be used to deliver the actual medicines to the patient. As such, we are cleared for market launch immediately upon proving Stability and Non-Inferiority of the API within our technology," Ross stated.

There is quite a track record to mention for the technology and its potential. Among raising all the money it ever needed for development, proving the concept and launching a worldwide investigation into optimal pharmaceutical delivery technologies, the SVS is a pioneer in being developed for humanitarian purposes firstly. Ross does not wish to make capital gains from the technology.

"I wish to merely repay the various investors and grant funders that have made this technology a reality. Beginning with a dream is one thing; reaching your goals is quite another. I know my strengths and I want to have the SVS reach the world today, if it were possible. As such, I will accept any offers for acquisition of the technology and all related IP and developments."

Ross found a solution that should maximize all returns on investment, from the philanthropic side to the commercial. "In the past, companies like Becton Dickinson have taken technologies to market with the vision of both philanthropic and commercial gains. Uniject, by Program for Appropriate Technology in Health, the first autodisable syringe is but one example. We wish to partner with a company like this or of a similar mindset, to truly reach the world through existing, trusted and capable suppliers," Ross outlined.

For the philanthropic side, he had this solution: "The Bill & Melinda Gates Foundation has helped us develop this from a blue sky idea with their early funding through the Grand Challenges Explorations Initiative in Round 8. I want the Gates Foundation to receive full, uninhibited rights to distribute the technology as it wishes around the world. I trust this will be met with agreement by any commercial manufacturer. We must make this available for vaccines in developing countries most of all. Everything else is minor in comparison."

For the remaining development, Ross said, "Program for Appropriate Technology in Health (PATH) not only has four years of development and validation experience with the SVS but also a track record of remarkable global health firsts. Steve Davis, Debbie Kristensen and Darin Zehrung, among others, launched our technology from a concept to a true, imminent potential reality. I would like to extend the offer to continue our collaboration in development until the technology is ready to be transferred to a competent global pharmaceutical packaging manufacturer."

With the above initiatives, SVS will become a reality and hopefully save many lives in the process. Ross said, "Imagine if PATH, Gates, the WHO and pharmaceutical partners took this over instead of myself. Just imagine how much better, faster, cheaper and more efficient the whole process will be. Why would I hold onto something that the world needs? I am not a selfish person and I want to make people realize how much good the above organizations do. Without the WHO, Gates, Royal Society of Edinburgh, Prince's Trust, Scottish Enterprise and PATH, we would be nowhere. Without them in the future, I fear the impact will be the same. Let's just do what needs to be done and my part is in making the above offers to the parties mentioned.

Ross is confident the response will be prompt and decisive. Partners worldwide can capitalize on making a true social investment with immense financial and psychological rewards.

For more information, please contact Ross directly via e-mail to rt@svsmedical.com.

For press inquiries, please contact Aimee Welsh via e-mail to aimeewelsh1@gmail.com.

By Aimee Welsh (aimeewelsh1@gmail.com)